MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) is the most common type of cancer among females worldwide and is associated with poor prognosis. Poly ADP-ribose polymerase-1 (PARP1) inhibitors are effective against TNBC with mutations in the breast cancer type 1 susceptibility protein (BRCA1) and/or BRCA2 gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaoqi, Jiang, Shanshan, Ruan, Simin, Guo, Zhaoze, Guo, Jingyun, Liu, Minfeng, Ye, Changsheng, Dong, Jianyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185508/
https://www.ncbi.nlm.nih.gov/pubmed/34080025
http://dx.doi.org/10.3892/mmr.2021.12187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185508/
https://www.ncbi.nlm.nih.gov/pubmed/34080025
http://dx.doi.org/10.3892/mmr.2021.12187

Ejemplares similares